Ignite Creation Date:
2025-12-24 @ 1:58 PM
Ignite Modification Date:
2026-01-01 @ 4:19 PM
Study NCT ID:
NCT00334295
Status:
COMPLETED
Last Update Posted:
2012-07-31
First Post:
2006-06-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Sponsor:
AstraZeneca
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
9238GR/0002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None